Abstract | INTRODUCTION: Over the last 15 years, clinical and experimental data have emerged that suggest that peripheral and central, glial-mediated neuroimmune activation is both necessary and sufficient to sustain chronic pain. Immune modulation appears to be, therefore, a possible new therapeutic option. MATERIALS AND METHODS: RESULTS: CONCLUSION:
IVIG therapy may emerge as a novel treatment modality for refractory cases. However, before this drug can be confidently used by clinicians, important questions need to be answered concerning optimal treatment doses, duration of treatment, and its effect on function and quality of life.
|
Authors | Andreas Goebel |
Journal | Journal of clinical immunology
(J Clin Immunol)
Vol. 30 Suppl 1
Pg. S103-8
(May 2010)
ISSN: 1573-2592 [Electronic] Netherlands |
PMID | 20424897
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Cytokines
- Immunoglobulins, Intravenous
|
Topics |
- Chronic Disease
- Complex Regional Pain Syndromes
(therapy)
- Cytokines
(metabolism)
- Fibromyalgia
(therapy)
- Humans
- Hyperalgesia
(etiology, physiopathology, therapy)
- Immunoglobulins, Intravenous
(therapeutic use)
- Mast Cells
(metabolism)
- Models, Immunological
- Models, Neurological
- Neuralgia
(therapy)
- Neuroglia
(metabolism)
- Nociceptors
(physiology)
- Pain
(physiopathology)
- Pain Management
- Posterior Horn Cells
(physiopathology)
- Postpoliomyelitis Syndrome
(therapy)
- Randomized Controlled Trials as Topic
- Sensory Receptor Cells
(physiology)
- Spinal Cord
(physiopathology)
|